9 results on '"Gong, Jianlin"'
Search Results
2. Current Immunotherapeutic Approaches in Pancreatic Cancer.
- Author
-
Koido, Shigeo, Homma, Sadamu, Takahara, Akitaka, Namiki, Yoshihisa, Tsukinaga, Shintaro, Mitobe, Jimi, Odahara, Shunichi, Yukawa, Toyokazu, Matsudaira, Hiroshi, Nagatsuma, Keisuke, Uchiyama, Kan, Satoh, Kenichi, Ito, Masaki, Komita, Hideo, Arakawa, Hiroshi, Ohkusa, Toshifumi, Gong, Jianlin, and Tajiri, Hisao
- Subjects
- *
PANCREATIC cancer , *CANCER treatment , *IMMUNOTHERAPY , *CANCER cells , *DRUG therapy - Abstract
Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vastmajority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, most patients do not survive longer than 6 months. Thus, new therapeutic approaches are needed. Pancreatic cancer cells that develop gemcitabine resistance would still be suitable targets for immunotherapy. Therefore, one promising treatment approach may be immunotherapy that is designed to target pancreatic-cancer-associated antigens. In this paper, we detail recent work in immunotherapy and the advances in concept of combination therapy of immunotherapy and chemotherapy. We offer our perspective on how to increase the clinical efficacy of immunotherapies for pancreatic cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
3. Dendritic/pancreatic carcinoma fusions for clinical use: Comparative functional analysis of healthy- versus patient-derived fusions
- Author
-
Koido, Shigeo, Hara, Eiichi, Homma, Sadamu, Namiki, Yoshihisa, Komita, Hideo, Takahara, Akitaka, Nagasaki, Eijiro, Ito, Masaki, Sagawa, Yukiko, Mitsunaga, Makoto, Uchiyama, Kan, Satoh, Kenichi, Arihiro, Seiji, Ohkusa, Toshifumi, Gong, Jianlin, and Tajiri, Hisao
- Subjects
- *
PANCREATIC cancer , *DENDRITIC cells , *CANCER cells , *BLOOD proteins , *COMPARATIVE studies , *TRANSFORMING growth factors , *INTERLEUKINS , *METASTASIS - Abstract
Abstract: Fetal calf serum (FCS)-independent pancreatic cancer cells were established in plasma protein fraction (PPF)-supplemented medium that is an agent of good manufacturing practice (GMP) grade. Dendritic cells (DCs) were activated with the Toll-like receptor agonist, penicillin-inactivated Streptococcus pyogenes (OK-432) that is also a GMP grade agent. Therefore, sufficient amounts of FCS-independent fusions were successfully generated with decreased potential hazards of FCS. The FCS-independent fusions expressed tumor-associated antigens, HLA-DR, costimulatory molecules, IL-12, and IL-10. Stimulation of T cells with fusions from healthy donors resulted in proliferation of T cells with high expression levels of perforin/granzyme B and IFN-γ and efficient induction of antigen-specific cytotoxic T lymphocytes (CTLs). Selection and expansion of T-cell clones were confirmed by TCR Vβ analysis. However, fusions from patients with metastatic pancreatic cancer induced increased expression levels of TGF-β1 in CD4+ CD25high T cells and low levels of CTLs with decreased IFN-γ production. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
4. Cancer Vaccine by Fusions of Dendritic and Cancer Cells.
- Author
-
Koido, Shigeo, Hara, Eiichi, Homma, Sadamu, Namiki, Yoshihisa, Ohkusa, Toshifumi, Gong, Jianlin, and Tajiri, Hisao
- Subjects
- *
CANCER vaccines , *DENDRITIC cells , *CANCER cells , *FUSION (Phase transformation) , *IMMUNE response - Abstract
Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells represents in many ways an ideal approach to deliver, process, and subsequently present a broad array of tumor-associated antigens, including those yet to be unidentified, in the context of DCs-derived costimulatory molecules. DCs/tumor fusion vaccine stimulates potent antitumor immunity in the animal tumor models. In the human studies, T cells stimulated by DC/tumor fusion cells are effective in lysis of tumor cells that are used as the fusion partner. In the clinical trials, clinical and immunological responses were observed in patients with advanced stage of malignant tumors after being vaccinated with DC/tumor fusion cells, although the antitumor effect is not as vigorous as in the animal tumor models. This review summarizes recent advances in concepts and techniques that are providing new impulses to DCs/tumor fusions-based cancer vaccination. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
5. In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells.
- Author
-
Koido, Shigeo, Homma, Sadamu, Hara, Eiichi, Mitsunaga, Makoto, Namiki, Yoshihisa, Takahara, Akitaka, Nagasaki, Eijiro, Komita, Hideo, Sagawa, Yukiko, Ohkusa, Toshifumi, Fujise, Kiyotaka, Gong, Jianlin, and Tajiri, Hisao
- Subjects
- *
T cells , *DENDRITIC cells , *LIVER cancer , *CANCER cells , *CELL culture , *ANTIGENS - Abstract
Background: Human hepatocellular carcinoma (HCC) cells express WT1 and/or carcinoembryonic antigen (CEA) as potential targets for the induction of antitumor immunity. In this study, generation of cytotoxic T lymphocytes (CTL) and regulatory T cells (Treg) by fusions of dendritic cells (DCs) and HCC cells was examined. Methods: HCC cells were fused to DCs either from healthy donors or the HCC patient and investigated whether supernatants derived from the HCC cell culture (HCCsp) influenced on the function of DCs/HCC fusion cells (FCs) and generation of CTL and Treg. Results: FCs coexpressed the HCC cells-derived WT1 and CEA antigens and DCs-derived MHC class II and costimulatory molecules. In addition, FCs were effective in activating CD4+ and CD8+ T cells able to produce IFN-γ and inducing cytolysis of autologous tumor or semiallogeneic targets by a MHC class I-restricted mechanism. However, HCCsp induced functional impairment of DCs as demonstrated by the down-regulation of MHC class I and II, CD80, CD86, and CD83 molecules. Moreover, the HCCsp-exposed DCs failed to undergo full maturation upon stimulation with the Toll-like receptor 4 agonist penicillin-inactivated Streptococcus pyogenes. Interestingly, fusions of immature DCs generated in the presence of HCCsp and allogeneic HCC cells promoted the generation of CD4+ CD25high Foxp3+ Treg and inhibited CTL induction in the presence of HCCsp. Importantly, up-regulation of MHC class II, CD80, and CD83 on DCs was observed in the patient with advanced HCC after vaccination with autologous FCs. In addition, the FCs induced WT1- and CEA-specific CTL that were able to produce high levels of IFN-γ. Conclusion: The current study is one of the first demonstrating the induction of antigen-specific CTL and the generation of Treg by fusions of DCs and HCC cells. The local tumor-related factors may favor the generation of Treg through the inhibition of DCs maturation; however, fusion cell vaccination results in recovery of the DCs function and induction of antigen-specific CTL responses in vitro. The present study may shed new light about the mechanisms responsible for the generation of CTL and Treg by FCs. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
6. Cell surface receptors for molecular chaperones
- Author
-
Calderwood, Stuart K., Theriault, Jimmy, Gray, Phillip J., and Gong, Jianlin
- Subjects
- *
CANCER cells , *MOLECULAR chaperones , *HEAT shock proteins , *TUMORS - Abstract
Abstract: Heat shock proteins are intracellular molecular chaperones. However, extracellular heat shock proteins have recently been shown to mediate a range of powerful effects in inflammatory cells, neuronal cells and immune cells. These effects are transmitted by a number of cell surface receptors including LRP/CD91, CD40, Toll-like receptors, Scavenger receptors and c-type Lectins. However, although extracellular heat shock proteins are products of at least five different gene superfamilies, similar receptor types often trigger their effects. We have assessed heat shock protein binding to the different receptor types with particular regard to its role in tumor immunology. Heat shock protein 70 released from dying tumor cells or injected as part of a vaccine induces a remarkable range of immune effects. This molecular chaperone induces powerful pro-inflammatory signaling cascades leading to the activation of antigen presenting cells. In addition, heat shock protein 70 is able to transport antigenic peptides as cargo from the tumor cell cytoplasm across the membranes of antigen presenting cells and deliver them to major histocompatability class I molecules, a process known as “cross-presentation”. The resulting major histocompatability class I-peptide complexes are then displayed on the cell surface by antigen presenting cells, leading to activation of cytotoxic T lymphocytes and tumor cell killing. Understanding how heat shock protein-receptor binding orchestrates individual components of tumor immunity will permit enhanced design of molecular chaperone based immunotherapy. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
7. Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells
- Author
-
Koido, Shigeo, Tanaka, Yasuhiro, Tajiri, Hisao, and Gong, Jianlin
- Subjects
- *
T cells , *IMMUNOTHERAPY , *DENDRITIC cells , *CANCER cells , *THERAPEUTICS - Abstract
Abstract: We have reported that fusions of patient-derived dendritic cells (DC) and autologous breast cancer cells induce T-cell responses against autologous tumors. However, the preparation of fusion cells requires patient-derived tumor cells, and these are not always available in the clinical setting. In the present study, we explore an alternative approach to constructing DC-breast cancer fusion vaccine by using breast caner-cell lines. DC generated from HLA-A*0201-positive donor were fused to HLA-A*0201+ allogeneic MCF7 breast cancer cells. These fusion cells co-expressed tumor-associated antigens and DC-derived costimulatory and MHC molecules. Both CD4 and CD8 T cells were activated by the fusion cells as demonstrated by the production of IFN-γ. The fusion cells induced strong antigen-specific cytotoxic T lymphocytes (CTL) activity against their parent cells. The lysis of targets was restricted by HLA-A*0201, since killing was blocked by the anti-HLA-A2 mAb. Similar CTL activity against HLA-A*0201-positive targets was induced when T cells were cocultured with fusions of DC and HLA-A*0201-negative allogeneic BT20 breast cancer cells. In addition, administration of T cells stimulated by DC-breast cancer fusion cells regressed 7-day-old tumors and rendered mice free of disease up to 90 days. These results suggest that tumor-cell lines can be used as a fusion partner in the construction of DC-tumor fusion vaccine. Such fusion cells hold promise since they can be used as a vaccine for active immunotherapy or as stimulators to activate and expand T cells for adoptive immunotherapy. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
8. research paper Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
- Author
-
Raje, Noopur, Hideshima, Teru, Davies, Faith E., Chauhan, Dharminder, Treon, Steven P., Young, Gloria, Tai, Yu-Tzu, Avigan, David, Gong, Jianlin, Schlossman, Robert L., Richardson, Paul, Kufe, Donald W., and Anderson, Kenneth C.
- Subjects
- *
IMMUNOTHERAPY , *CANCER cells , *DENDRITIC cells , *VACCINES , *MULTIPLE myeloma , *LYMPHOCYTES , *T cells - Abstract
Multiple myeloma (MM) cells express certain tumour-associated antigens (TAAs) that could serve as targets for active-specific immunotherapy. The aim of the present study was to test the MM/dendritic cell (DC) fusion as a vaccination strategy. We fused MM cells with DC to generate fusion cells (FCs) and tested their antigen presenting cell (APC) function in mixed lymphocyte reactions and cytotoxicity assays. First, the HS Sultan and SK0-007 HAT sensitive human MM cell lines and DCs generated from peripheral blood of normal donors were fused in the presence of 50% polyethylene glycol to form FCs. Next, tumour cells freshly isolated from patients were similarly fused with autologous DCs to generate FCs. The FCs demonstrated a biphenotypic profile, confirmed both by flow-cytometry and dual immunofluorescence microscopy. These FCs induced MM-specific cytotoxicity. FCs, but not MM cells or DCs alone, were potent stimulators of autologous patient T cells. More importantly, FC-primed autologous peripheral blood mononuclear cells demonstrated major histocompatibility complex-restricted MM-specific cytolysis. These studies therefore demonstrated that MM/DC FC can trigger an autologous immune response to MM cells and formed the framework for a clinical trial currently underway. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
9. The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions.
- Author
-
Shigeo Koido, Sadamu Homma, Masato Okamoto, Yoshihisa Namiki, Kazuki Takakura, Kan Uchiyama, Mikio Kajihara, Toshifumi Ohkusa, Gong, Jianlin, and Hisao Tajiri
- Subjects
- *
CHEMICAL agonists , *DENDRITIC cells , *CANCER cells , *IMMUNE response , *IMMUNOSUPPRESSIVE agents - Abstract
The induction of antitumor immune responses by dendritic cell (DC)/tumor cell fusions can be modulated by their activation status. Our recent work reveals that the combination of toll-like receptor 2 (TLR2) and TLR4 agonists promotes the immunogenicity of DC/tumor cell fusions, allowing them to overcome the immunosuppressive efects of transforming growth factor β1. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.